Our researchers combine imagination with the rigor of collaborative science to find better treatments for disease.

Novartis Institutes for BioMedical Research (NIBR)

The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. We collaborate across scientific and organizational boundaries, with a focus on powerful new technologies that have the potential to help produce therapeutic breakthroughs for patients.

We carry out research at Novartis at six locations globally: Cambridge, Massachusetts; San Diego, California; Emeryville, California; East Hanover, New Jersey; Basel, Switzerland; Shanghai, China.

Disease Areas

We focus on discovering and advancing new treatments for serious patient needs. From the inception of a therapy through early clinical development, our disease area teams collaborate across scientific disciplines and organizations in support of our mission to improve and extend peoples’ lives.

Cardiovascular and Metabolic Diseases investigates and develops transformative therapies to improve outcomes and quality of life for patients with atherosclerosis, heart failure, arrhythmia, and metabolic diseases.

Diseases of the nervous system have a dramatic impact on patients and families around the world. These diseases are among the greatest contributors to disability and mortality affecting more than two billion people. Our mission is to reduce human suffering by developing treatments for serious diseases of the nervous system.

Milena working at NIBR

5 months with Novartis, and already within the first week I joined a global project spanning across various functions, stakeholders & countries. There’s no better way to learn about a new company than by getting involved in a live project right from the get-go!

Milena, Senior Consultant

Novartis Institutes for BioMedical Research Oncology and Hematology is uniquely positioned to create new standards of care for cancer patients. We combine key learnings from the clinic with hypothesis-driven preclinical research to identify novel targets and develop effective medicines using various treatment modalities, including targeted therapy, radioligand therapy, T Cell Therapy, and antibody drug conjugates. We strive to tackle the most challenging issues in cancer and deliver medicines that transform the lives of cancer patients.


The Ophthalmology DU has expanded to form Development Unit x (“DUx”) to reflect the portfolio of programs that have potential to deliver high-value innovation but are not aligned to our core Development Units and therapeutic areas.

Disease Area X catalyzes and drives transformative therapies for emerging, high-potential indications. Our current research focuses on liver diseases, kidney diseases, and fibrosis.


These research groups have deep expertise in technologies and disciplines that are relevant to multiple disease areas. They support drug discovery teams across Novartis Institutes for BioMedical Research.

Our mission is to create new modalities that tackle complex biology and enable the production of quality biotherapeutics, which translate innovative ideas of Novartis investigators into medicines. To reach this goal, we rely on our scientists by nurturing an inspiring environment of intellectual curiosity and open collaboration with our partners.

We catalyze early drug discovery by integrating our diverse expertise across biology, chemistry, data and technology to translate scientific advances and enable the discovery of innovative therapeutics. Empowered project teams are at the center of our culture of curiosity and open collaboration.

Global Discovery Chemistry operates with the goal to efficiently create a continuous stream of innovative medicines through scientific excellence and strong collaboration across disciplines. We aim to discover and develop breakthrough molecules by boldly enabling unprecedented biological space with suitably crafted compounds across diverse chemical modalities, in partnership with our disease area and platform colleagues.

PK Sciences is an enterprise organization, working across both Novartis Institutes for BioMedical Research and the Global Drug Development organizations to advance the scientific knowledge of pharmacokinetics, metabolism and clinical pharmacology, playing a pivotal role in bridging drug discovery and clinical application.

Preclinical Safety provides world class preclinical safety profiling and assessment for optimal drug discovery, development, and commercialization with state-of-the-art regulatory compliance. We achieve this together with our internal partners as a global organization working in an environment of mutual trust and respect.


These groups serve as the crucial bridge between drug discovery and clinical application. Physician-scientists and researchers specialize in integrating findings from early drug discovery projects with their own deep knowledge of disease pathways and unmet medical needs.

Biomarker Development enables testing of biological and therapeutic hypotheses in clinical trials by developing and analyzing innovative biomarkers spanning molecular, cellular, imaging and digital device modalities. Their quality work contributes significantly to Novartis’ goal of delivering high value, differentiated medicines to patients.

Clinical Sciences & Innovation executes and oversees the majority of the Translational Medicine clinical portfolio worldwide. Our associates strive to support a smooth transition from discovery research to clinical practice – driven by a strong focus on clinical & data sciences, clinical innovation, patient centricity and strategic planning.

Discovery & Profiling drives innovative science from discovery to the patient through the selection, profiling and effective development of medicines. The global Discovery & Profiling group includes Translational Medicine Experts with a strong background in both biological research and clinical practice. Their dual experience helps them identify optimal indications for new drugs.

Novartis Institutes for BioMedical Research Oncology is uniquely positioned to create new standards of care for cancer patients through a combination of treatment approaches including targeted therapies, immunotherapies, CAR-T, and radioligand therapy.


Novartis Institutes for BioMedical Research global Translational Medicine group builds on basic research advances to develop new therapies that address unmet medical need. We are the crucial bridge between drug discovery and clinical application. Through our work, we increase the speed, quality and productivity of drug discovery and development by Novartis and play a pivotal role in bringing innovative medicines to patients.

Novartis Institutes for BioMedical Research (NIBR) Global Health

NIBR Global Health is dedicated to the research and discovery of drugs to treat neglected tropical diseases, which disproportionately affect vulnerable populations in predominantly low- to middle- income countries. Our current focus is on parasitic diseases (malaria, Chagas disease, leishmaniasis, cryptosporidiosis) and viral infection (Flavivirus such as dengue, Yellow Fever, Coronavirus and Henipavirus).

Find your Career in Research and impact the lives of millions.

Career Search